Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31245544 | 0.88 | TAAR1 (0.54) | TAAR1IDO1ALDH1A1TSHRHTT | |
| SCHEMBL2541735 | 0.88 | TAAR1 (0.54) | TAAR1IDO1ALDH1A1TSHRHTT | |
| SCHEMBL15110409 | 0.84 | TAAR1 (0.43) | TAAR1IDO1ALDH1A1TSHRHTT | |
| SCHEMBL15184061 | 0.81 | TSHR (0.39) | TAAR1IDO1ALDH1A1TSHRDAO | |
| SCHEMBL2810417 | 0.80 | TSHR (0.36) | TAAR1ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL3208584 | 0.79 | TAAR1 (0.46) | TAAR1IDO1ALDH1A1GAATSHR | |
| SCHEMBL500370 | 0.78 | TAAR1 (0.48) | TAAR1IDO1ALDH1A1TSHRHTT | |
| SCHEMBL5365120 | 0.78 | TAAR1 (0.44) | TAAR1IDO1ALDH1A1TSHRHTT | |
| SCHEMBL8819214 | 0.78 | TAAR1 (0.52) | TAAR1ALDH1A1TSHRHPGDDAO | |
| SCHEMBL4450889 | 0.77 | TAAR1 (0.56) | TAAR1IDO1TSHRPYCR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9890231-B2 | Triarylphosphine or triarylarsine compound, alpha-olefin polymerization catalyst using the compound, ternary copolymer, and production process of alpha-olefin-((meth)acrylic acid)-based copolymer | JAPAN POLYETHYLENE CORPORATION (JP) | 2018-02-13 | — | — | US | disclosed |
| US-20160264699-A1 | NOVEL TRIARYLPHOSPHINE OR TRIARYLARSINE COMPOUND, ALPHA-OLEFIN POLYMERIZATION CATALYST USING THE COMPOUND, TERNARY COPOLYMER, AND PRODUCTION PROCESS OF ALPHA-OLEFIN -((METH)ACRYLIC ACID)-BASED COPOLYMER | JAPAN POLYETHYLENE CORPORATION (JP) | 2016-09-15 | — | — | US | disclosed |
| US-9376459-B2 | Triarylphosphine or triarylarsine compound, alpha-olefin polymerization catalyst using the compound, ternary copolymer, and production process of alpha-olefin-((meth)acrylic acid)-based copolymer | JAPAN POLYETHYLENE CORPORATION (JP) | 2016-06-28 | — | — | US | disclosed |
| EP-2190811-B1 | RENIN INHIBITORS | MERCK CANADA INC (CA) | 2013-08-07 | — | — | EP | disclosed |
| US-8334308-B2 | Renin inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-12-18 | — | — | US | disclosed |
| US-8334308-B2 | Renin inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-12-18 | — | — | US | disclosed |
| US-8334308-B2 | Renin inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-12-18 | — | — | US | disclosed |
| US-20120035214-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-02-09 | — | — | US | disclosed |
| US-20120035214-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-02-09 | — | — | US | disclosed |
| US-20120035214-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-02-09 | — | — | US | disclosed |
| EP-2413941-A1 | RENIN INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20110263658-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2011-10-27 | — | — | US | disclosed |
| US-20110263658-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2011-10-27 | — | — | US | disclosed |
| US-20110263658-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2011-10-27 | — | — | US | disclosed |
| US-20110257351-A1 | NOVEL TRIARYLPHOSPHINE OR TRIARYLARSINE COMPOUND, ALPHA-OLEFIN POLYMERIZATION CATALYST USING THE COMPOUND, TERNARY COPOLYMER, AND PRODUCTION PROCESS OF ALPHA-OLEFIN -((METH)ACRYLIC ACID)-BASED COPOLYMER | JAPAN POLYPROPYLENE CORPORATION (JP) | 2011-10-20 | — | — | US | disclosed |
| WO-2010114978-A1 | RENIN INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-10-07 | — | — | WO | disclosed |
| EP-2190811-A1 | RENIN INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009023964-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257351-A1 | NOVEL TRIARYLPHOSPHINE OR TRIARYLARSINE COMPOUND, ALPHA-OLEFIN POLYMERIZATION CATALYST USING THE COMPOUND, TERNARY COPOLYMER, AND PRODUCTION PROCESS OF ALPHA-OLEFIN -((METH)ACRYLIC ACID)-BASED COPOLYMER | AS3MT, ATR, ALK | TAAR1 25/4885IDO1 1474/4885ALDH1A1 641/4885 |
| US-20110263658-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | TAAR1 2165/4885IDO1 3738/4885ALDH1A1 1379/4885 |
| US-20120035214-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | TAAR1 1781/4885IDO1 3324/4885ALDH1A1 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.